期刊
PEERJ
卷 10, 期 -, 页码 -出版社
PEERJ INC
DOI: 10.7717/peerj.13141
关键词
Desmoglein 2; Cancer; Prognosis; Systematic review; Meta-analysis
资金
- Scientific Research Foundation of the Health Planning Committee of Sichuan [18PJ186]
- National Natural Science Foundation of China [81600864]
- Undergraduate Student Innovation and Entrepreneurship Training Program of Sichuan University [C202114146]
- Swedish Cancer Society [19-0056-JiA]
This systematic review and meta-analysis found that high expression of Desmoglein 2 (DSG2) is associated with worse prognosis in patients with non-small cell lung cancer (NSCLC), suggesting that DSG2 expression could serve as a biomarker for prognosis in NSCLC.
Objective: The survival and clinicopathological significance of desmoglein 2 (DSG2) in various cancers is controversial. Thus, we performed this systematic review and meta-analysis to explore the preliminary prognostic value of DSG2. Methods: Eligible studies were identified from databases including PubMed, the Cochrane Library, Embase, Web of Science and Scopus. Hand searches were also conducted in relevant bibliographies. We then extracted and pooled hazard ratio (HR) of overall survival (OS) and odds ratio (OR) of clinicopathological features. Results: A total of 11 eligible studies containing 1,488 patients were included. Our results demonstrated that in non-small cell lung cancer (NSCLC), high DSG2 expression is associated with poor OS. However, in digestive system cancer and female reproductive system cancer, there were no statistically significant associations between OS and DSG2. Conclusions: Based on the findings of this study, high DSG2 expression is associated with worse prognosis in patients with NSCLC, and thus DSG2 expression could be a biomarker for prognosis in NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据